Shots:

• The approval is based on the P-II JULIET (NCT02445248) trial results assessing Kymriah (tisagenlecleucel) in patients with 1L+ DLBCL and followed by NICE approval in for pediatric and aged <25 yrs. with B-cell acute lymphoblastic leukemia (ALL) in Sep-2018
• The P-II JULIET results; 18mos.@ median relapse-free survival rate 64%; OR 43%; safe and effective
• Kymriah is a CAR-T (chimeric antigen receptor T cell) therapy and has also received the US FDA approval for patients with relapsed/refractory (R/R) large B-cell lymphomas

   Ref: Nice | Image: Wikipedia